Thriving biotech: three stocks building momentum
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
List view / Grid view
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.